Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., Jurcic, J. G., Larson, R. A., Liu, C., Ritchie, E., Schiller, G., Spira, A. I., Strickland, S. A., Tibes, R., Ustun, C., Wang, E. S., Stuart, R., Röllig, C., Neubauer, A., Martinelli, G., Bahceci, E., & Levis, M. (n.d.). selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet oncology, 18(8), 1061–1075. http://access.bl.uk/ark:/81055/vdc_100049766196.0x000013